Sage Therapeutics to Present at Upcoming August Investor Conferences
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:
- 2021 Wedbush PacGrow Healthcare Virtual Conference: Barry Greene, Chief Executive Officer of Sage Therapeutics, will be a featured speaker on the panel, The Brains of the Operation - Novel Approaches in Neuro, on Tuesday, August 10, 2021 at 12:00 p.m. ET.
- Canaccord Genuity 41st Annual Growth Conference: fireside chat on Wednesday, August 11, 2021 at 8:00 a.m. ET.
A live webcast of each event can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005867/en/
Jeff Boyle
617-949-4256
[email protected]
Maureen L. Suda
617-949-4289
[email protected]
Source: Sage Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
- TP-Link Unveils World’s First Complete Wi-Fi 8 Lineup at IFA 2026 — Regional Pre-Orders to Start on September 30th
- Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share